Heart Test Laboratories (NASDAQ:HSCS – Get Free Report) is one of 50 public companies in the “Surgical appliances & supplies” industry, but how does it weigh in compared to its competitors? We will compare Heart Test Laboratories to similar companies based on the strength of its valuation, dividends, profitability, analyst recommendations, institutional ownership, risk and earnings.
Earnings and Valuation
This table compares Heart Test Laboratories and its competitors top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Heart Test Laboratories | N/A | -$6.35 million | -0.82 |
| Heart Test Laboratories Competitors | $1.23 billion | $98.82 million | 44.89 |
Heart Test Laboratories’ competitors have higher revenue and earnings than Heart Test Laboratories. Heart Test Laboratories is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Heart Test Laboratories | N/A | -644.85% | -148.59% |
| Heart Test Laboratories Competitors | -187.46% | -141.02% | -24.97% |
Volatility & Risk
Heart Test Laboratories has a beta of 3.92, suggesting that its stock price is 292% more volatile than the S&P 500. Comparatively, Heart Test Laboratories’ competitors have a beta of 0.94, suggesting that their average stock price is 6% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings for Heart Test Laboratories and its competitors, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Heart Test Laboratories | 0 | 0 | 2 | 0 | 3.00 |
| Heart Test Laboratories Competitors | 350 | 1124 | 2346 | 92 | 2.56 |
Heart Test Laboratories presently has a consensus target price of $3.15, suggesting a potential upside of 370.15%. As a group, “Surgical appliances & supplies” companies have a potential upside of 111.59%. Given Heart Test Laboratories’ stronger consensus rating and higher probable upside, analysts plainly believe Heart Test Laboratories is more favorable than its competitors.
Institutional and Insider Ownership
4.2% of Heart Test Laboratories shares are held by institutional investors. Comparatively, 45.8% of shares of all “Surgical appliances & supplies” companies are held by institutional investors. 14.6% of Heart Test Laboratories shares are held by insiders. Comparatively, 10.7% of shares of all “Surgical appliances & supplies” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Heart Test Laboratories competitors beat Heart Test Laboratories on 7 of the 13 factors compared.
About Heart Test Laboratories
Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.
Receive News & Ratings for Heart Test Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heart Test Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
